Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection (2020)

Peer-Reviewed Study · de Castro CG, Gregianin LJ, Burger JA · October 2020

de Castro CG et al., 2020-10: Research letter reporting continuous daily high-dose ivermectin given to patients with acute myelogenous leukemia, the principal published example of uninterrupted daily dosing in humans.

de Castro CG et al., 2020-10: Research letter reporting continuous daily high-dose ivermectin given to patients with acute myelogenous leukemia, the principal published example of uninterrupted daily dosing in humans. C2 long-term daily dosing. Record field: the PubMed record carries no abstract (publication types Letter, Comment) and the publisher (Taylor & Francis) copy is paywalled, so no body text was read and key_excerpt is empty; confidence MEDIUM. Study type: research letter / case observations in patients with AML (patient-reported clinical observations, not a trial); N not stated in the indexed record. Country: Brazil (Santa Casa de Porto Alegre, Porto Alegre, RS). Dose: continuous daily oral ivermectin at high dose – the letter's own dose figures sit in the paywalled body and are NOT quoted here. Funder and declared conflicts: not in the indexed record. This is the citation the 'continuous dosing' claim rests on; a verifier needing dose and N must obtain the letter itself. Also filed as IVA-27 (claims C2, C6). Study type: other.